[{"address1": "One Main Street", "address2": "Suite 1350", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 410 4650", "website": "https://www.cullinanoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 85, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nadim  Ahmed", "age": 55, "title": "President, CEO & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 1160516, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey  Jones M.B.A., M.D., M.P.H.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 780321, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick A. Baeuerle Ph.D.", "age": 65, "title": "Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 763734, "exercisedValue": 0, "unexercisedValue": 3785044}, {"maxAge": 1, "name": "Dr. Jennifer  Michaelson Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacquelyn L. Sumer J.D.", "age": 45, "title": "Chief Legal Officer, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rose  Weldon", "title": "Senior Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Andre", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Corinne  Savill Ph.D.", "age": 64, "title": "Chief Business Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin A. Johnston", "title": "Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.67, "open": 17.38, "dayLow": 16.4, "dayHigh": 17.55, "regularMarketPreviousClose": 16.67, "regularMarketOpen": 17.38, "regularMarketDayLow": 16.4, "regularMarketDayHigh": 17.55, "beta": 0.326, "forwardPE": -4.9101796, "volume": 122437, "regularMarketVolume": 122437, "averageVolume": 427858, "averageVolume10days": 275950, "averageDailyVolume10Day": 275950, "bid": 16.38, "ask": 16.51, "bidSize": 100, "askSize": 100, "marketCap": 706275840, "fiftyTwoWeekLow": 7.64, "fiftyTwoWeekHigh": 19.68, "fiftyDayAverage": 17.3482, "twoHundredDayAverage": 11.80215, "currency": "USD", "enterpriseValue": 254619296, "floatShares": 25875131, "sharesOutstanding": 43065600, "sharesShort": 1436008, "sharesShortPriorMonth": 694101, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.033299997, "heldPercentInsiders": 0.06397, "heldPercentInstitutions": 0.95242995, "shortRatio": 3.12, "shortPercentOfFloat": 0.040999997, "impliedSharesOutstanding": 44899900, "bookValue": 10.576, "priceToBook": 1.5506808, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -153162000, "trailingEps": -3.69, "forwardEps": -3.34, "enterpriseToEbitda": -1.338, "52WeekChange": 0.54781806, "SandP52WeekChange": 0.23416412, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CGEM", "underlyingSymbol": "CGEM", "shortName": "Cullinan Oncology, Inc.", "longName": "Cullinan Oncology, Inc.", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "df7e2588-017b-3d57-acc4-780da62c5adc", "messageBoardId": "finmb_539392639", "gmtOffSetMilliseconds": -14400000, "currentPrice": 16.4, "targetHighPrice": 34.0, "targetLowPrice": 19.0, "targetMeanPrice": 25.5, "targetMedianPrice": 25.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 467067008, "totalCashPerShare": 10.845, "ebitda": -190339008, "totalDebt": 3590000, "quickRatio": 16.6, "currentRatio": 17.066, "debtToEquity": 0.791, "returnOnAssets": -0.22798, "returnOnEquity": -0.31368, "freeCashflow": -88761624, "operatingCashflow": -134275008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-15"}]